Q-omics provides the consensus-scored ARHGAP36 profile across patient tissues and cancer cell-line models. ARHGAP36 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ARHGAP36 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, ARHGAP36 RNA expression shows 11,179 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where ARHGAP36 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARHGAP36 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARHGAP36 survival associations across molecular data types. ARHGAP36 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARHGAP36 RNA expression–survival associations across cancer types. High ARHGAP36 expression shows unfavorable associations in KIRC, UCEC and BLCA, but favorable associations in UVM, ACC and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ARHGAP36 RNA expression.
This table summarizes ARHGAP36 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ARHGAP36. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARHGAP36 shows lower tumor expression in COAD, HNSC, BRCA, READ and KIRC and higher tumor expression in THCA. The COAD box plot shows higher ARHGAP36 RNA expression in normal versus tumor tissue (log2 FC = −0.262, t-test p < 0.001).
This table shows molecular features associated with ARHGAP36 in patient tissues and cancer cell lines. In patient samples, ARHGAP36 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ARHGAP36 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
